EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial

Philip Heesen, Stefan Feuerriegel, Olga Ciobanu-Caraus, Andreas Ranft, Vivek Bhadri, Benedicte Brichard, Stephane Collaud, Sona Cyprova, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes und 13 weitere

European Journal of Cancer · 2026-07 · 243 · 116825

DOI: 10.1016/j.ejca.2026.116825 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-07. Verfasst von Philip Heesen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics III, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, Essen 45147, Germany; Faculty of…. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Bone Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Standard Ewing sarcoma treatment includes chemotherapy and local therapy. Previous studies found no average treatment effect of combined local therapy (radiotherapy and surgery) versus surgery alone, leaving it unclear which patients benefit from combined therapy. METHODS: We analysed patients with localized Ewing sarcoma from the EURO-E.W.I.N.G. 99 and Ewing 2008 trials. Using causal survival forests validated through repeated k-fold cross-validation, we predicted individualized treatment effects (ITEs) for 5-year event-free survival (5y EFS) comparing combined therapy to surgery alone. We developed a personalized treatment rule and evaluated ITE predictors using Shapley additive explanations analysis. RESULTS: Of 1501 patients, 719 received combination therapy and 782 surgery alone. Predicted ITEs showed substantial heterogeneity (range: -0.7-1.0 years). We found that 19.4% of patients derived clinically meaningful benefit (5y EFS increase ≥6 months) from combined therapy. In the quartile predicted to benefit least, hazards of any event were increased by 53% (HR 1.53, 95% CI 1.06-2.20, p = 0.02). Conversely, in the quartile predicted to benefit most, hazards were reduced by 40% (HR 0.60, 95% CI 0.42-0.85, p = 0.004). In patients undergoing combined treatment, surgical margin status was not associated with treatment benefit. A simulation analysis showed that applying our treatment strategy could improve EFS. DISCUSSION: Our predicted ITEs can help identify patients benefiting from combined therapy. The finding that patients with non-wide surgical margins did not benefit from combined therapy challenges current decision-making practices based on traditional subgroup analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingBone NeoplasmsHumansFemaleMaleAdolescentTreatment Effect HeterogeneityChildChild, PreschoolCombined Modality TherapyYoung AdultAdultTreatment Outcome

Stichwörter der Autor:innen

Ewing sarcomacausal machine learningindividualized treatment effectsradiotherapysarcoma

Autor:innen und Institutionen

  • Pediatrics III, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, Essen 45147, Germany; Faculty of Medicine, University of Zurich, Raemistrasse 71, Zurich 8006, Switzer…
  • Munich Center for Machine Learning (MCML), Munich, Germany; LMU Munich, Munich, Germany.
  • Interventional Neuroradiology, Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Pediatrics III, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, Essen 45147, Germany; German Cancer Consortium (DKTK), and National Center for Tumor diseases (NCT), P…
  • Chris O´ Brien Lifehouse, Camperdown, Australia Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales 2006, Australia.
  • Cliniques Universitaires Saint Luc, Department of Pediatric Haematology and Oncology, Université Catholique de Louvain, Av. Hippocrate 10, Brussels 1200, Belgium.

Zitieren

APA

Heesen, P., Feuerriegel, S., Ciobanu-Caraus, O., Ranft, A., Bhadri, V., Brichard, B., Collaud, S., Cyprova, S., Eich, H., Ek, T., Gelderblom, H., Hardes, J., Haveman, L., Hartmann, W., Hauser, P., Juergens, H., Kanerva, J., Kühne, T., Raciborska, A., …, & Dirksen, U. (2026). Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial. European Journal of Cancer, 243, 116825. https://doi.org/10.1016/j.ejca.2026.116825

Vancouver

Heesen P, Feuerriegel S, Ciobanu-Caraus O, Ranft A, Bhadri V, Brichard B, et al. Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial. European Journal of Cancer. 2026;243:116825. doi:10.1016/j.ejca.2026.116825

BibTeX
@article{Heesen2026,
  author = {Heesen, Philip and Feuerriegel, Stefan and Ciobanu-Caraus, Olga and Ranft, Andreas and Bhadri, Vivek and Brichard, Benedicte and Collaud, Stephane and Cyprova, Sona and Eich, Hans and Ek, Torben and Gelderblom, Hans and Hardes, Jendrik and Haveman, Lianne and Hartmann, Wolfgang and Hauser, Peter and Juergens, Heribert and Kanerva, Jukka and Kühne, Thomas and Raciborska, Anna and Rascon, Jelena and Streitbürger, Arne and Timmermann, Beate and Uhlenbruch, Yasmin and Fuchs, Bruno and Dirksen, Uta},
  title = {Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {243},
  pages = {116825},
  doi = {10.1016/j.ejca.2026.116825}
}
Kostenlos starten →